Ahmedabad: Zydus Lifesciences Limited has announced that the Company has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture and market Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial, (RLD: RADICAVA).
Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease).

Amyotrophic lateral sclerosis (ALS) is a rare and terminal neurodegenerative disease that results in the progressive loss of motor neurons. Motor neurons control voluntary muscles. ALS is the most common form of the motor neuron diseases. Early symptoms of ALS include muscle twitches, stiff muscles, muscle wasting, and gradual increasing weakness.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), had annual sales of USD 19 mn. in the United States (IQVIA MAT Jan-24). The group now has 390 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences wins USFDA nod for Chlorpromazine Hydrochloride Injection for certain mental disorders
team had earlier reported that Zydus had received permission from CDSCO, India, to initiate the Phase II clinical study of NLRP3 inhibitor “ZYIL1” in patients with Amyotrophic Lateral Sclerosis (ALS).
Read also: Zydus Lifesciences gets CDSCO nod to begin Phase II clinical trial of ZYIL1 in Amyotrophic Lateral Sclerosis patients
Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 26,000 people worldwide, including 1,400 scientists engaged in R & D.
Read also: Zydus Healthcare gets CDSCO Panel Nod To study FDC Empagliflozin plus Metoprolol Succinate